RASSF1C Oncogene Elicits Amoeboid Invasion, Cancer Stemness, and Extracellular Vesicle Release via a SRC/Rho Axis

Investigators showed that the novel oncogene RASSF1C drove mesenchymal-to-amoeboid transition and stem cell attributes in breast cancer cells. Mechanistically, RASSF1C activated Rho/ROCK via SRC-mediated RhoGDI inhibition, resulting in generation of actomyosin contractility.